We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Astellas Completes Acquisition of OSI Pharmaceuticals PR Newswire TOKYO, June 9 TOKYO, June 9 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that the company has completed its...
Astellas Announces Successful Completion of Tender Offer for Shares of OSI Subsequent Offer Period Has Expired; Merger to be Completed Shortly PR Newswire TOKYO, June 8 TOKYO, June 8 /PRNewswire/...
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP; the “Company”) announced today that its 2% Convertible Senior Subordinated Notes due 2025 (the “notes”) are convertible at the option of...
Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period PR Newswire TOKYO, June 3 TOKYO, June 3 /PRNewswire/ -- Astellas Pharma...
Standard & Poor's Announces Changes to U.S. Indices PR Newswire NEW YORK, May 26 NEW YORK, May 26 /PRNewswire/ -- S&P SmallCap 600 constituent Tractor Supply Co. (Nasdaq: TSCO) will replace OSI...
Expiration Date of OSI Offer Extended to June 2, 2010 PR Newswire TOKYO, May 17 TOKYO, May 17 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that it had extended its all-cash...
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. Companies enter into definitive merger agreement to combine to create a world-class oncology platform OSI Stockholders to receive $57.50...
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for...
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva® (erlotinib) as an...
Expiration Date of OSI Offer Extended to May 17, 2010 PR Newswire TOKYO, April 23 TOKYO, April 23 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that it has extended its...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions